Last reviewed · How we verify
L-NMMA
L-NMMA, developed by The Methodist Hospital Research Institute, is a marketed drug with a key composition patent expiring in 2028. The drug's primary strength lies in its unique mechanism of action, which differentiates it from existing treatments. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | L-NMMA |
|---|---|
| Also known as | iNOS inhibitor, NOS Inhibition, NG-monomethyl-L-arginine, L-N-Monomethyl-arginine, NG-monomethyl-l-arginine |
| Sponsor | The Methodist Hospital Research Institute |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) (PHASE2)
- Passive Limb Movement: A Tool to Assess Vascular Health and Guide Rehabilitation
- : Vascular Function in Health and Disease (PHASE1)
- Mechanisms of Vasovagal Syncope (EARLY_PHASE1)
- Phase Ib of L-NMMA and Pembrolizumab (PHASE1)
- Anemia Study in Chronic Kidney Disease (CKD) : Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat -Forearm Blood Flow (ASCEND-FBF) (PHASE2)
- L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (PHASE1, PHASE2)
- Prostacyclin (PGI2) Pathway to Enhance Wound Healing in Diabetic Foot Ulcers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-NMMA CI brief — competitive landscape report
- L-NMMA updates RSS · CI watch RSS
- The Methodist Hospital Research Institute portfolio CI